US Bancorp’s Mural Oncology MURA Stock Holding History

US Bancorp’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-37	Closed	-$116	–	4155
2024 Q2	$116	Hold	37	–	–	﹤0.01%	3928
2024 Q1	$181	Sell	37 -104	-74%	-$505	﹤0.01%	3913
2023 Q4	$835	Buy	+141	New	+$567	﹤0.01%	3815

Other funds holding MURA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

US Bancorp's MURA Position: Q3 2024 in Review

US Bancorp sold out of Mural Oncology (MURA) in Q3 2024, closing a stake of 37 shares — an estimated $116 sold.

US Bancorp first reported a position in MURA in Q4 2023 and held it in 3 quarters. The position peaked at $835 in Q4 2023. 74 funds tracked by Wall St. Rank hold MURA as of Q3 2024.

US Bancorp reported no remaining Mural Oncology position as of Q3 2024 after selling out during the quarter.
US Bancorp sold 37 Mural Oncology shares in Q3 2024, an estimated $116.
US Bancorp first reported a position in Mural Oncology in Q4 2023 and held it in 3 quarters.
US Bancorp's Mural Oncology position peaked at $835 in Q4 2023.
74 funds tracked by Wall St. Rank held Mural Oncology as of Q3 2024.

Based on US Bancorp's 13F filing for Q3 2024, filed 28 Oct 2024.